StemCell Therapy

By Elizabeth Johnson

Leading pharmaceutical and biotechnology companies chose INTERPHEX 2017 to launch their newest products, with 20 companies debuting new technology at the pharmaceutical and biotechnology industry trade show held March 21-23 at the Jacob K. Javits Convention Center in New York City.

In its 38th year, INTERPHEX offered attendees a mix of content including more than 104 conference education sessions, INTERPHEX Live discussions, hundreds of exhibits and product launches.

The show experienced attendee growth, compared with 2016, and attributes much of that to its robust program.

INTERPHEX offers its customers the opportunity to bring their entire teams and engage in education for everyone, said Melissa Ashley, senior vice president of INTERPHEX.

She continued, Attendance is free to those who register ahead to support the industry and allow companies full teams to experience all that is happening in the industry.

Having grown and evolved from a regional to a national and international event, INTERPHEX selected New York as its home because the city is a gateway that allows people to come from abroad and because there are a lot of customers in the tri-state area.

INTERPHEX is reflective of the industry advancing to the future, with organizers working to ensure the needs of technology companies are on display.

Still, the biotechnology industry is slower to change than some industries because it is heavily regulated, according to Kate Scott McCorriston, director of marketing and technical content for INTERPHEX.

The regulations mean people need to attend to learn about new guidance and regulations, McCorriston explained.

She added, Young professionals need to attend to learn how to manufacture new products within regulations and cost-effectively.

Unique features such as INTERPHEX Live keep attendees engaged.

Unlike standard panels or lectures or even exhibitor-led education, INTERPHEX Live discussions allow participants to ask questions and engage in a direct dialogue with experts, with sessions taking place out in the open and not far from registration, making it easy for people to join the discussions.

In addition, INTERPHEX organizers solicit customer feedback to make sure they are hitting the mark with show programming.

We ask, who do they want more of and what research do they need? Ashley said.

She continued, Then, we put that information together with feedback from our technical advisory board in order to create the best program we can.

In addition to showcasing the latest technology, the show itself uses a lot of technology to provide the best experience for attendees and exhibitors, including online matchmaking tools pre-show so that attendees can customize their experience and understand who they want to target before they arrive.

The show invested in a lead retrieval tool that helps exhibitors really know who they are talking to as well.

We want people to engage, not just walk up and down the aisles and leave, Ashley explained.

The goal of INTERPHEXs show organizers was to reach more attendees using the technology they had available, and it appears they got their wish, with a positive response to those tools.

INTERPHEX is sponsored by the Parenteral Drug Association (PDA) and brings over 11,500 global industry professionals and more than 625 industry-leading suppliers together to Learn it, Experience it, Procure it annually.

INTERPHEX 2018 will take place April 19-21 at the Javits Center.

Continued here:
20 New Biotechnology Products Debut at INTERPHEX 2017 - TSNN Trade Show News (blog)

NEW YORK, NY / ACCESSWIRE / March 31, 2017 / Prana Biotechnology and Xenetic Biosciences both saw their company's stock prices soar on news of a broader, more global product distribution. Prana is continuing to expand its presentation of PBT-434, while Xenetic is moving ahead with its strategic planning goals to make its product technology available to a larger geographical area.

RDI Initiates Coverage:

Prana Biotechnology Limited https://ub.rdinvesting.com/news/?ticker=PRAN

Xenetic Biosciences Inc. https://ub.rdinvesting.com/news/?ticker=XBIO

Prana Biotechnology advanced 37.65% to close at $3.40 on Thursday. The stock traded in a wide range between $4.58 and $2.75 during the day on a volume of 11.95 million shares traded. The company has presented new data from its Reach2HD trial at the American Neurological Association Annual Meeting held in Baltimore. Its primary candidate drug, PBT-434, demonstrated pre-clinical evidence that the drug will help with the treatment of movement disorders of patients with Parkinson's Disease.

Prana Biotechnology, an Australian company, for the half-year period ending December 31, 2016, reported total operating expenses of $6.05 million AUD, a pre-tax income of $3.65 million AUD, and a loss of $0.68 AUD per share.

Access RDI's Prana Biotechnology Research Report at: https://ub.rdinvesting.com/news/?ticker=PRAN

Xenetic Biosciences accelerated to advance 44.30% to close at $5.44 on Thursday. The stock traded between $5.61 and $3.87 on volume of 180,793 shares traded. Xenetic has been aggressively promoting its products internationally, and the rise in price is due in part to it becoming a member of the NASDAQ community on March 30th. The company has been expanding its patent portfolio to a number of countries, including Europe and the United States. Currently, their major marketable product is PolyXen technology platform. The product's IP on its PolyXen technology platform will afford protection on average for the next 10 to 12 years.

The latest financial report with period ending September 30, 2016, showed the company posting $2.25 million in operating expenses, a net loss of $2.47 million, and net loss per share of $0.28 and it had about $212,000 of cash assets on its books as on September 30th.

Access RDI's Xenetic Biosciences Research Report at: https://ub.rdinvesting.com/news/?ticker=XBIO

Our Actionable Research on Prana Biotechnology Limited (NASDAQ: PRAN) and Xenetic Biosciences Inc. (NASDAQ: XBIO) can be downloaded free of charge at Research Driven Investing.

Research Driven Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and reviewed by Nadia Noorani, CFA charter holder. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at http://www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

contact@rdinvesting.com

CFA and Chartered Financial Analyst are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com

Original post:
Prana Biotechnology and Xenetic Biosciences Expand Their Product Promotion - Yahoo Finance

Prana Biotechnology Limited (ADR) (NASDAQ:PRAN)

Prana Biotechnology Limited (ADR) (NASDAQ:PRAN) shares have been up over 80% on large volumes. PRAN closed yesterday at $2.48, gapped up to open at $2.95, reached an inter-day high of $4.58, and are now trading around $3.60 for an inter-day gain of over 45%. The nano-cap Australian-based biotech firm has, prior to todays action, an average daily trading volume of just over 59,000 but, by 10:30 AM EST, PRAN shares had already traded over 7.1 million times. A review of news services reveals that no news has been reported by the company or an analyst that could account for todays price action.

Prana Biotechnology Limited (ADR) (NASDAQ:PRAN) is a clinical stage biotechnology firm that develops therapeutic medicines. Prana has developed PBT-2 for the treatment of Alzheimers disease. PBT-2 is currently in a Phase IIa clinical trial. Pranas PBT-2 is also being investigated for applications involving other therapeutic applications including age-related cataracts, Huntington disease, Creutzfeldt-Jakob disease, Motor Neuron disease, age-related macular degeneration, cancers, Parkinsons disease, and other neurodegenerative diseases.

When PRAN is adjusted for dilutive effects, the shares high came in early 2014 when PRAN was trading near $80/share. However, by the end of 2014, PRAN shares would end up down over 74%. Dilution, EPS losses, and weak sales figures have plagued the shares. Prana Biotechnology Limited (ADR) (NASDAQ:PRAN) have reported sales of $100,000 every year since 2012 except for 2014 when the company reported a figure of $300,000. EPS losses have been noteworthy. In 2012 the EPS loss for shares holders of PRAN was -$5.00, followed by annual EPS losses of-$6.31, -$8.55, -$3.21, and -$3.98 in 2016. There has also been consistent dilution for PRN shareholders. In 2012 the number of outstanding shares was 800,000 and that number grew annually and in 2016 the number was 1.48 million. Given Prana Biotechnology Limited (ADR) (NASDAQ:PRAN) market cap of only $23 million and its lack of sales, no analysts have reviewed the companys share ratings since 2014.

I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 96 hours. All information, or data, is provided with no guarantees of accuracy.

About the author: Marc has a degree in economics and a MSc. in Finance. Over his 20-year career, Marc has worked for global investment firms in Europe and the United States as an analyst, fund manager, and consultant.

Marc Anderson is a pseudonym. Marc has a degree in economics and a MSc. in Finance. Marc worked for global investment firms in Europe and the United States as an analyst, fund manager, and consultant. View all posts by Marcus Anderson

Excerpt from:
Prana Biotechnology Limited (ADR) (NASDAQ:PRAN) Gains are ... - StockNewsUnion

Technology and biotechnology stocks once again top our list of momentum charts to watch.

Achaogen Inc. AKAO, +7.49% had an important snapback session on Tuesday, gaining $2.12, or 9.7%, to $23.90 on over 2 million shares traded. The move came on news that venture capitalist Robert Duggan disclosed a 5.7% stake in the late-stage biopharmaceutical company. Volume was the strongest on an up-day all year, and the stock has now bounced off rising trendline support after a 10-day pullback from the top of the channel to the bottom. If the stock can get through resistance, which is now up around Tuesdays high at $24.46, it could challenge recent highs around $26.75-$27.75 on the way to the top of the channel at over $30.

Cara Therapeutics Inc. CARA, +6.08% had a nice follow-through on Tuesday, jumping 94 cents, or 5%, to $19.09, on 7.6 million shares traded. The biotech company reported positive results in a trial of a treatment for uremic pruritus, or UP. The stock reached $20.24 intraday, the highest its been since September 2015. It came down in the afternoon and didnt close great, but from the standpoint of the daily pattern as well technicals and volume, the stock looks strong. It has climbed nicely off rising trendline support toward mid-channel in the past two weeks. The stock needs to hold lateral support at around $17.50. A move through Tuesdays high could lead to $23 short-term and $27 intermediate-term.

Kopin Corp. KOPN, -0.37% maker of wearable technologies and display products, had nice action on Tuesday, especially in the afternoon when it ran from about $3.90 to $4.19, backing off a little at the close. Net on the day, it gained 8 cents, or 2%, to $4.11 on strong volume of 643,000 shares. Volume has been strong in general in the past few weeks, indicating possible accumulation, and Tuesday saw the stock edge above its breakout point at around $4.09. Watch for $4.75 and then $5-$5.25 as targets.

Nektar Therapeutics NKTR, +1.13% had a breakout session on Tuesday, up 55 cents, or 2%, to $23.93 on 1.7 million shares. The company announced on Monday it has begun dosing in a Phase 1 study of its new biologic therapy to treat auto-immune diseases and inflammatory disorders. The move broke the stock out of a week-long consolidation zone that followed its nearly 50% gap up on March 20. The move came on only average volume. Nonetheless, watch for a run at $26 short-term.

Western Digital Corp. WDC, +1.66% is on the move. Stock in the data-storage company has been up five days in a row since its March 21 close at $73.22. Investors appear to have been encouraged by Micron Technologys MU, -0.66% strong quarterly forecast late last week, and optimism about memory and storage chip demand. On Tuesday, WDC gained $1.99, or 2.5%, to $80.56, on nearly 4 million shares traded. The stock is right at a lateral resistance level, and a pop through there could get it to $86-$87 and then the channel top near $95.

See Harrys video chart analysis on these stocks.

Harry Boxer is founder of TheTechTrader.com, a live trading room featuring his stock picks, technical market analysis, and live chart presentations.

Original post:
Harry Boxer's five technology and biotechnology stocks to watch ... - MarketWatch

A Little Vertex Goes a Long Way For Biotechnology - Barron's Barron's Healthcare stocks are the second-best performing, behind just the information technology sector year-to-date. Healthcare stocks have gained 8.3%, while the ... and more »

Go here to read the rest:
A Little Vertex Goes a Long Way For Biotechnology - Barron's - Barron's

Share This Article: Crowds enter the BIO exhibit hall near the California booth in 2014. Photo by Chris Jennewein

The BIO International Conventionreturns to San Diego after three years, bringing more than 16,000 to the San Diego Convention Center in June.

The event from June 19 to 22is expected to attract many of the top business and scientific leaders in the life sciences industry. There will be 1,800 exhibitors, and former British Prime Minister David Cameron is scheduled to give a keynote address.

BIO last held its convention in San Diego in 2008 and 2014. The 2014 event drew 15,667, including nearly 2,500 company CEOs,from all 50 states and 70 countries.

BIO is pleased to return to San Diego, one of the worlds largest and most innovative centers for biotechnology development, said Jim Greenwood, BIO President and CEO. This event provides biotech leaders with opportunities to showcase their breakthrough innovations, partner with C-level executives and network with the global biotech industry.

San Francisco was the location of last years convention, and Greenwood said its not surprising for the state to host two in a row because it remains the world leader in life sciences.

Biocom welcomes BIO 2017 to San Diego, where the sun reflects on our citys astonishing breadth and depth of life science innovation and success, said Joe Panetta, President and CEO of the trade group BIOCOM.

Discounted, advanceregistration for the conference ends on April 10.

>> Subscribe to Times of San Diegos free daily email newsletter! Click here

Read this article:
Giant Biotechnology Convention Returns to San Diego in June - Times of San Diego

KARACHI: Pakistani agro-scientist should expedite their research activities in agro-biotechnology in order to create significant impact in enhancing agriculture production in the country.

Talking to the Daily Times, agro-biotechnology experts and agriculturists on cotton, maize, corn and other crops said Pakistan should follow the developed world and developing nations like The Philippines and India who have already made significant economic progress by adopting the latest agri-technologies.

Though Pakistan has been conducting regulatory field trials and research on ground for biotech cotton and corn but there was the need to exploit more avenues introduced in the modern agro-base technologies in the world.

The concerned government departments and ministry should also allocate more funds in this sector in the upcoming annual budget, they opined.

"Cotton has remained a vital cash crop and country needs above 16 million bales every crop season, as cotton related textile sector feeds a large number of direct and indirect employment besides textile export stands number one on five prime exporting sectors", President of Sindh Agriculture Forum, Shakeel Ahmad said.

The positive impact of biotech crops around the world is evident in reducing pesticide usage, which is subsequently a positive for the environment, he added.

Cotton, corn and wheat would continue to be important crops for our economy and farmers therefore we must continuously apply better technologies.

Water availability for agriculture is going down and while this will require major decisions, biotechnology can help in growing crops, which utilise less water and fertilizers.

Ahmad said there was dire need of biotechnology induction especially in major crops, as textile sector bore around $15-$20 billion on imports annually.

Greater velocity in research activities will help in improving rural farm incomes and bring positive economic impact to people in the traditional corn and cotton belts as well the northern parts of the country, cotton expert and patron-in-chief Pakistan Cotton Ginners Association, Rana Abdul Sattar said.

Pakistan should focus on attaining sustainable higher yields and better water management to avert food shortages in the coming two decades.

An expert on Life Sciences, Punjab University described biotechnology benefits for farmers and outlined the achievements in attaining enhanced maize and corn yields by farmers.

Bacillus Thuringiensis (Bt) maize and corn provides excellent season-long protection against the target pests like corn borer and stalk borer.

Corn contains a natural occurring protein (Bt) that helps protect plants from specific lepidopteron insect pests. They said with a growing population it is imperative that Pakistan should focus on attaining sustainable higher yields and better water management to avert food shortages in the coming two decades.

We need to be more focused and take quick decisions. The 21st century has begun with a population of 6.2 billion and likely to increase to 9.2 billion by 2050.

Continue reading here:
Scientists asked to expedite research in agro-biotechnology - Daily Times

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:

JD Supra provides users with access to its legal industry publishing services (the "Service") through its website (the "Website") as well as through other sources. Our policies with regard to data collection and use of personal information of users of the Service, regardless of the manner in which users access the Service, and visitors to the Website are set forth in this statement ("Policy"). By using the Service, you signify your acceptance of this Policy.

JD Supra collects users' names, companies, titles, e-mail address and industry. JD Supra also tracks the pages that users visit, logs IP addresses and aggregates non-personally identifiable user data and browser type. This data is gathered using cookies and other technologies.

The information and data collected is used to authenticate users and to send notifications relating to the Service, including email alerts to which users have subscribed; to manage the Service and Website, to improve the Service and to customize the user's experience. This information is also provided to the authors of the content to give them insight into their readership and help them to improve their content, so that it is most useful for our users.

JD Supra does not sell, rent or otherwise provide your details to third parties, other than to the authors of the content on JD Supra.

If you prefer not to enable cookies, you may change your browser settings to disable cookies; however, please note that rejecting cookies while visiting the Website may result in certain parts of the Website not operating correctly or as efficiently as if cookies were allowed.

Users who opt in to receive emails may choose to no longer receive e-mail updates and newsletters by selecting the "opt-out of future email" option in the email they receive from JD Supra or in their JD Supra account management screen.

JD Supra takes reasonable precautions to insure that user information is kept private. We restrict access to user information to those individuals who reasonably need access to perform their job functions, such as our third party email service, customer service personnel and technical staff. However, please note that no method of transmitting or storing data is completely secure and we cannot guarantee the security of user information. Unauthorized entry or use, hardware or software failure, and other factors may compromise the security of user information at any time.

If you have reason to believe that your interaction with us is no longer secure, you must immediately notify us of the problem by contacting us at info@jdsupra.com. In the unlikely event that we believe that the security of your user information in our possession or control may have been compromised, we may seek to notify you of that development and, if so, will endeavor to do so as promptly as practicable under the circumstances.

Except as otherwise described in this privacy statement, JD Supra will not disclose personal information to any third party unless we believe that disclosure is necessary to: (1) comply with applicable laws; (2) respond to governmental inquiries or requests; (3) comply with valid legal process; (4) protect the rights, privacy, safety or property of JD Supra, users of the Service, Website visitors or the public; (5) permit us to pursue available remedies or limit the damages that we may sustain; and (6) enforce our Terms & Conditions of Use.

In the event there is a change in the corporate structure of JD Supra such as, but not limited to, merger, consolidation, sale, liquidation or transfer of substantial assets, JD Supra may, in its sole discretion, transfer, sell or assign information collected on and through the Service to one or more affiliated or unaffiliated third parties.

This Website and the Service may contain links to other websites. The operator of such other websites may collect information about you, including through cookies or other technologies. If you are using the Service through the Website and link to another site, you will leave the Website and this Policy will not apply to your use of and activity on those other sites. We encourage you to read the legal notices posted on those sites, including their privacy policies. We shall have no responsibility or liability for your visitation to, and the data collection and use practices of, such other sites. This Policy applies solely to the information collected in connection with your use of this Website and does not apply to any practices conducted offline or in connection with any other websites.

We reserve the right to change this Policy at any time. Please refer to the date at the top of this page to determine when this Policy was last revised. Any changes to our privacy policy will become effective upon posting of the revised policy on the Website. By continuing to use the Service or Website following such changes, you will be deemed to have agreed to such changes. If you do not agree with the terms of this Policy, as it may be amended from time to time, in whole or part, please do not continue using the Service or the Website.

If you have any questions about this privacy statement, the practices of this site, your dealings with this Web site, or if you would like to change any of the information you have provided to us, please contact us at: info@jdsupra.com.

- hide

Link:
Biotechnology Innovation Organization's Amicus Brief in Sandoz v. Amgen - JD Supra (press release)

NEW YORK, March 27, 2017 /PRNewswire/ -- Use this report to:- Analyze existing and future agricultural biotechnology products and technologies that will be commercially important. - Receive a qualitative and quantitative description of the agricultural biotechnology industry. - Highlight key market and industry trends, as well as quantify the main market segments. - Receive information on agricultural biotechnologies, market applications, industry structure and competitive dynamics.

Highlights- The global market for agricultural biotechnology reached $29.2 billion in 2016. This market should reach $32.1 billion in 2017 and $53.7 billion in 2022, with a compound annual growth rate (CAGR) of 10.8%. - Genomic-enabled products as a segment reached $24.1 billion in 2016, and should reach nearly $26.5 billion in 2017 and $43.7 billion in 2022, with a CAGR of 10.6%.

STUDY GOALS AND OBJECTIVES BCC Research's goal for this study is to determine the specific applications and forecast global market demand for agricultural biotechnology products over a five-year period from 2017 through 2022. The main objective is to characterize and quantify the agricultural biotechnology products market by product type, geography, and purpose. In addition, the report analyzes the industry structure, competitors, strategic alliances, and intellectual property landscape. A total of 70 companies in the industry are profiled.

Agricultural biotechnology markets analyzed in this report include biotechnology tools, genomics enabled products, and biologicals. Biotechnology tools include DNA sequencing, biochips, RNA interference, synthetic biology, and genome editing. Genomics enabled products include biotech seeds and synthetic biology-enabled products. Biologicals include biopesticides, biostimulants, and genetic biologicals.

A key objective of the report is to provide a comprehensive analysis of the agricultural biotechnology industry, with an emphasis on products and technologies that are commercially important in the 2017 to 2022 time-period. Market segments with rapid growth rates are highlighted, as well as those segments with large market potential. This analysis provides a quantitative basis and market context for companies to make strategic choices about participation in the agricultural industry.

The study will be particularly useful to those companies developing new genomics or proteomics technologies; discovering and development novel seed traits; doing plant breeding; interested in using novel biotechnologies in agriculture; or working inadvanced biotechnology fields like genome editing, synthetic biology, RNA interference, biochips, or DNA sequencing.

The study will also be useful to government agencies or institutions that are developing strategic initiatives for a country's agriculture policy and/or industry.

REASONS FOR DOING THE STUDY

Agriculture is a fundamental and strategic component for a country. As a result, agricultural technologies provide competitive geographic advantage and are highly desirable. Biotechnologies address the pressing industry need for higher crop yields. Agricultural biotechnology is a key and growing component of the global agriculture industry and is thus of interest to a wide audience.

This report seeks to provide a qualitative and quantitative description of the agricultural biotechnology industry so that emerging market opportunities can be identified and exploited by the reader.

The report does this by examining the main product applications and markets, helping companies to prioritize product opportunities and strategic opportunities. The report highlights key market and industry trends, as well as quantifying the main market segments. The reader is thus able to better understand industry structure and changes occurring in the industry.

Rapid changes in technology-intensive fields such as DNA sequencing, genome editing, and synthetic biology are driving new products and applications in agriculture. These developments create unique market opportunities. This report analyzes these trends and their impact on future markets for agricultural products.

Based on these market and technology dynamics, it is especially timely to examine the agricultural biotechnology industry.

INTENDED AUDIENCE

Read More

This study examines and analyzes existing and future agricultural biotechnology products and technologies that will be commercially important.

Markets are presented by product type, crop type, and geographical region. Important market segments covered include the main biotechnologies (DNA sequencing, biochips, RNA interference, synthetic biology tools, and genome editing tools) as well as synthetic biology-enabled chemicals and biofuels, biotech seeds, and biologicals.

In-depth coverage is provided for agricultural biotechnologies; growth driving forces; market applications; industry structure and competitive dynamics; companies and industry alliances; future market potential and product sales forecasts for the period 2017 through 2022. The report forecasts the future value of agricultural biotechnology products by product type and geography.

This report will be of particular interest to agriculture, chemicals, bio-energy, and biotechnology companies; as well as suppliers of genomics tools, synthetic biology, RNA interference, and DNA sequencing products. It will also be of interest to professionals within governments, think tanks, and regulatory agencies to understand the end uses of these technologies in agriculture.

SCOPE AND FORMAT

The study scope includes key agricultural biotechnology tools (i.e., next generation DNA sequencing, biochips, RNA interference, synthetic biology tools and genome editing tools); synthetic biology-enabled chemicals and biofuels; biotech seeds; and biologicals.

BCC analyzes these technologies and products to determine present and future market sizes, and forecasted growth from 2017 through 2022. The report also discusses industry strategic alliances, industry structures, competitive dynamics, patent status, and market driving forces.

BCC provides in-depth coverage of the agricultural biotechnology industry structure, including genomics technology providers (e.g., genome editing, NGS, microarray companies); major seed companies; biotech traits companies; synthetic biology tools companies; companies developing plant feedstocks; and agricultural biologicals companies. It provides an in-depth analysis of major industry acquisitions and alliances during 2015 and 2016.

70 agricultural and biotechnology companies are profiled in this report.

METHODOLOGY

BCC Research examined key users and producers in each of the enduser market segments and technology fields that will be commercially important during the next five years. Discussions with industry thought leaders, as well as secondary market research was performed.

Based on our analysis, we project the future applications of agricultural biotechnologies in the major enduser market segments and by technology type, and forecast sales revenues for 2017 through 2022.

INFORMATION SOURCES

BCC Research performed primary and secondary research for this report. Primary sources included key industry companies and leading research institutions. In addition, data were compiled from secondary sources, including company websites and industry, trade and government publications. Read the full report: http://www.reportlinker.com/p0958100-summary/view-report.html

About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

http://www.reportlinker.com

__________________________ Contact Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/agricultural-biotechnology-emerging-technologies-and-global-markets-300429907.html

Read the rest here:
Agricultural Biotechnology: Emerging Technologies and Global ... - Yahoo Finance

With excellent mechanical and chemical stability, the Kromasil EternityXT materials offer first-rate separation power and loadability for purification from low to high pH. Kromasil EternityXT C8 and C18 materials can operate up to pH 12, making it possible to run basic compounds under extreme conditions to improve purification productivity and reduce costs. These products support discovery, development and production departmental goals in the purification of a low molecular weight pharmaceuticals, peptides and biotechnology products.

The exceptional structure of Kromasil EternityXT C18 and C8 materials makes it possible to regenerate the material in-column, carrying out cleaning in place (CIP) even at 1 M NaOH, if so required. While this high concentration NaOH treatment is a standard in bio chromatography and until now only conceivable with polymer resins, Kromasil EternityXT materials open up the spectrum of purification options as its C8 and C18 materials resist up to 1 M NaOH.

See the article here:
Purification of Pharmaceutical and Biotechnology Products with Kromasil EternityXT Stationary Phase - Labmate Online

By Nicolas Chahine, InvestorPlace Contributor|Mar 28, 2017, 11:13 am EDT

It would seem that the toxicity that the iShares Nasdaq Biotechnology Index (ETF) (NASDAQ:IBB) were suffering on Wall Street is waning. Until recently, the political headlines were a threat to all healthcare and biotech stock holders.The thesis that biotech stocks are untouchable, however, is no longer the dark cloud that it was.

So can I buy the IBB long from here with confidence? Not in my opinion. I think that trading the IBB should fit into a bullish macro scenario, which we may no longer have. Equity markets are near all-time highs with few catalysts that are not yet priced in. Traders quickly priced in the fiscal spending and legislative advantage that President Trump promised. This week we saw the first promise die, so the onus is now on the bulls to prove they can deliver the rest.

Click to EnlargeSo to say the least, the perfectly bullish scenario has some rebuilding to do. This creates an opportunity to take a short-term bearish bet on the IBB. I can do this without spending any out-of-pocket money.

Before you label me a bear, I am merely shorting the near-term price action and not the fundamentals of any components within the IBB. In fact, I will leverage their value to pay for my bet.

The Trade: Buy the IBB June $280/$275 debit put spread for $1.30. This is a bearish trade that could triple my money if IBB falls through my spread before mid-June. The cost of entry is my maximum potential loss. I usually like to hedge my bets, and in this case, I will sell downside risk against the value of the IBB. The trick is to find proven support zones.

The Bank: Sell the IBB Jan $200 put and collect $3 per contract. The current 30% price buffer gives this leg a 90% theoretical chance of success. As long as IBB stock stays above my January sold strike, any premium I recover from selling the June debit put spread would be pure profit. Having no out-of-pocket risk makes managing this trade relatively easy.

Fair warning: Selling puts is risky, so only do it if you are willing and able to own the IBB shares at the strike price.

Nicolas Chahine is the managing director of SellSpreads.com. Learn options as easy as 1-2-3 here. As of this writing, he did not hold a position in any of the aforementioned securities. You can follow him on Twitter at @racernicand stocktwits at@racernic.

Article printed from InvestorPlace Media, http://investorplace.com/2017/03/short-the-ishares-nasdaq-biotechnology-index-etf-ibb-etf/.

2017 InvestorPlace Media, LLC

Read this article:
IShares Nasdaq Biotechnology Index: Short the Near-Term Action in ... - Investorplace.com

OTTAWA, Ontario--(BUSINESS WIRE)--

Canada's biotech industry today welcomed the federal budget and its measures supporting the advancement of Canadian innovation in biotechnology centered sectors such as health/bio-sciences, clean technology and agri-food. Importantly the budget proposes support for the acceleration of innovation through the establishment of sector specific superclusters, including health/bio-sciences, agri-food and clean technology.

"The core of our industry is innovation - much of it coming out of universities. The Budgets focus on innovation and creating super clusters in biotechnology centered fields including health/bio-sciences, agri-food, and clean technology recognizes Canadas strengths in these areas and the enormous opportunity for the economy in successfully advancing biotechnology innovation. Today's commitments will result in products and therapies of the future and will accelerate the use of biotechnology in supporting the global competitiveness of Canadas traditional cornerstone economic sectors of agriculture, forestry, mining, energy and advanced manufacturing," commented Andrew Casey, President and CEO BIOTECanada.

Drawing on the nation's rich legacy of research, Canada now has an opportunity to become one of the worlds most successful modern biotech regions by transitioning its traditional industries into the new economy while drawing on its considerable strength of its investment in research. From universities, small mid-sized companies, hospitals and public research agencies across the country, Canadian biotech scientists make up the ecosystem ensuring Canadas biotechnology sector thrive.

Importantly, Canada already has in place many of the components necessary for global competitiveness and success in biotechnology. Indeed, Canada is home to a number of regional clusters which bring together: world-class universities and research institutes; biotech entrepreneurs; a significant multinational industry presence; and, a highly educated workforce. All told, the Canadian national biotech ecosystem is an economic strength that positions Canada well to compete in the emerging global bio-economy. The Budget will help harness many of these strengths to accelerate Canadas biotechnology innovation progress.

BIOTECanada looks forward to working with the federal government over the months ahead, offering a coordinated set of recommendations and mechanisms for the announced programs. Implementation consultations are key to ensuring the commitments realize the potential they offer to the biotechnology industry.

View source version on businesswire.com: http://www.businesswire.com/news/home/20170322006371/en/

Link:
BIOTECanada: Federal Budget Strengthens Biotechnology Industry Ecosystem Building Canadian Economy - Yahoo Finance

Buy, Sell or Hold? Analysts Approach: Innoviva (INVA), Puma Biotechnology (PBYI)? The USA Commerce Shares of Puma Biotechnology, Inc. (NASDAQ:PBYI) dropped -2.02% to $38.90. During the trading on 03/27/2017, Company's stock ranged from $39.70 to $38.15. The relative strength index or RSI highlights overbought (above 70) and oversold (below 30) ... Watch List: Puma Biotechnology Inc (NASDAQ:PBYI) , Red Rock Resorts, Inc (NASDAQ:RRR)NYSE Journal (press release) all 3 news articles »

See the original post here:
Buy, Sell or Hold? Analysts Approach: Innoviva (INVA), Puma Biotechnology (PBYI)? - The USA Commerce

What happened

Cellect Biotechnology (NASDAQ:APOP), an Israeli-based stem-cell company, today announced the first successful stem cell transplant procedure using its ApoGraft technology in a combined phase 1/2 clinical trial in a blood cancer patient, causing its shares to rise by as much as 115%. The company's stock has since cooled off, but is still up by 80% as of 3:00 p.m. EDT.

Image source: Getty Images.

Even though stem cell transplants can be a curative treatment for many blood disorders and blood-related cancers, they tend to be a treatment of last resort because of their life-threatening side effects, such as graft-versus-host disease (GvHD). So, if Cellect's ApoGraft technology turns out to be a viable workaround, it would be a major advancement in the field, and potentially an extremely lucrative product for the company.

While Cellect's announcement is indeed exciting, its stock still isn't a great long-term bet. Cellect exited 2016 with a paltry $8 million in cash andApoGraft is probably five to six years away from reaching the market. This current trial, after all, is simply a safety and proof-of-concept study that's not designed to provide a basis for a regulatory approval.

In addition, Bellicum Pharmaceuticals'adjunct T-cell therapy BPX-501 could reach the European market as one possible solution to the GvHD problem in blood cancer patients by early 2019, and in the U.S. by perhaps 2020. In other words, Bellicum has a significant head start on Cellect, which may diminish the commercial prospects ofApoGraft moving forward.

George Budwell has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

See original here:
Why Cellect Biotechnology Stock Is Skyrocketing Today - Motley Fool

Prof. Lucy Ogbadu is the director-general of the National Biotechnology Development Agency (NABDA). In his interview with NKECHI ISAAC, she talks about the current state of agricultural biotechnology development in Nigeria.

How many confined field trials are currently going on in Nigeria?

We have four confined field trials presently going on in Nigeria. They are BT Cowpea in Ahmadu Bello University, Institute of Agricultural Research, Zaria; African Bio-fortified Sorghum going on at the Ahmadu Bello University, Institute of Agricultural Research; BT Cotton equally being handled by IAR, Zaria; Newest Rice being handled by the National Cereals Research Institute, Badeggi.

How are the crops doing, how will you access their performance?

They are doing very well, were impressed with their performance. The BT Cowpea and ABS are ahead of the other two in the sense that they started earlier in 2011 and they have progressed tremendously. They are already into multi-locational trials as well as on-farm trials, especially the BT Cowpea.

When are you looking at harvesting these crops?

We harvest them periodically because there is no staple crop that grows for this length of time from 2011. So, obviously weve been harvesting and collecting the data on them, so it is not the issue of when we harvest because none of them grows more than a period of four to five months. So, weve been harvesting and studying them further.

When are we looking at commercialising these crops, the target was previously 2018 but it has been shifted to 2019. Can the nation make this new timeline?

The BT Cowpea will most likely be the first to go out for commercialisation and it will not go beyond 2019 in the sense that we want to be doubly sure on all were doing with the crop. The scientists are happy with the results they are getting, the farmers working with the scientists are equally happy with the results theyre getting in terms of out-performing the conventional ones theyve been used to. So, hopefully by 2019 latest, it should be out in the market.

Are there any regulatory hurdles that remain before these crops can be successfully commercialised in Nigeria?

Looking from the perspective of the government in terms of policy, there are no hurdles because the establishment of this agency by the government shows the government is in support of biotechnology. Now in terms of regulation all the risk assessment, all stewardship in terms of its performance have all been carried out by our scientists that are handling the crops.

This is about the last stage of what they need to do before it is commercialised in the sense that the seeds need to be multiplied before we can say they are ready for release but of course other regulatory hurdle that may interest you is that of registration of the crop with our varietal release committee, a unit based at Ibadan which will require them to convene a meeting of the varietal release committee to look at all the descriptors that are required to be looked at before they are registered and adjudged ready for release. That is about the only hurdle that is left.

After commercialization, how accessible will this crop be to the local farmers at the grassroots who are supposed to be the main benefactors of this technology?

They wont be different from all other seeds in the sense that once they are considered okay for commercial release then it will be at the national centre for genetic resources and biotechnology in Ibadan and at that stage the only thing that will be left will be for multiplication. You know the PIs will handle the multiplication along with the extension workers after which they will be ready for uptake for farmers that are interested and other interested people.

Seed companies are sceptical about genetically modified seeds, theyre scared that multinational seed companies like Monsanto and the likes will take over their market once GM crops are produced?

The process were currently adopting shows that our scientists and farmers are involved. Now if it gets to the stage of uptake and our indigenous Nigerian seed companies refuse to come forward to take them for multiplication and release them they shouldnt blame other seed companies that come forward to multiply them. In this case our own seed companies will definitely participate in the multiplication and release. I am sure of that. They should be able to come forward and participate because the qualities of the seeds are attractive so they should be able to come forward and take them up.

No foreign seed company will jump over the laid down protocols to come and introduce any foreign seed to Nigeria, it is not possible because the regulatory framework is in place to ensure that does not happen.

Some school of thoughts believe we should channel efforts at reducing food wastage instead of applying biotechnology to boost agriculture and ensure food security. What is your take on this?

Agricultural biotechnology is not limited to GMO alone. In fact the same technology can be applied to crops in order to check the food wastage, prolong the shelf life of agricultural produce, it can be applied to crops to ensure that improved yield of crops. So, there are various ways this technology can be used advantageously on crops. It can also be used to improve the nutritional quality of the crops. So, it is not limited to GM and as a matter of fact GM is only a technique that can give us so many other advantages. This is why we feel the public should trust our scientists enough to leave the matter to them because it is a complex scientific process that people who do not really understand science cant understand. The same technology can be used to improve the shelf life of tomato for instance such that it can stay on the shelf for much longer period without spoiling.

We cannot make any serious progress in agriculture without applying biotechnology; were talking about using agriculture to diversify Nigerias economy, if that is so how else other than mechanisation. In addition to mechanisation you must have quality seeds, deploy technology in order to use agriculture to diversify the economy. It is not with our crude system of agriculture that we can use it to diversify the economy. What this simply means is that were losing a lot if we do not use advanced technology, which is agricultural biotechnology to diversify the economy.

Through advanced agricultural biotechnology we can revolutionise agriculture and ensure food security using agricultural biotechnology. To downplay on it means the nation is losing heavily and invariably unserious about diversifying the economy through agriculture. Theres no other way, it is through agricultural biotechnology that we can inject and revolutionise agriculture to diversify Nigerias economy.

Follow this link:
We Can't Diversify Economy Through Agriculture Without Biotechnology Ogbadu - Leadership Newspapers

StockNewsJournal

Why Investors remained confident on Puma Biotechnology, Inc. (PBYI), Tempur Sealy International, Inc. (TPX)? StockNewsJournal Puma Biotechnology, Inc. (PBYI) have shown a high EPS growth of -44.40% in the last 5 years and has earnings decline of -11.30% yoy. Analysts have a mean recommendation of 1.90 on this stock (A rating of less than 2 means buy, hold within the 3 range ... and more »

The rest is here:
Why Investors remained confident on Puma Biotechnology, Inc. (PBYI), Tempur Sealy International, Inc. (TPX)? - StockNewsJournal

PUMA BIOTECHNOLOGY, INC. (NASDAQ:PBYI) Files An 8-K Changes in Registrant's Certifying Accountant Market Exclusive Puma Biotechnology, Inc. is a biopharmaceutical company that focuses on the development and commercialization of products for the treatment of cancer. The Company focuses on in-licensing the global development and commercialization rights to over ...

See the original post here:
PUMA BIOTECHNOLOGY, INC. (NASDAQ:PBYI) Files An 8-K Changes in Registrant's Certifying Accountant - Market Exclusive

Biotechnology is a popular trend that can be found in various aspects of our everyday lives. While it is true biotechnology is a very complicated concept to grasp, it is also one of the most promising technologies to be found today. Biotechnology will help our society address some of its greatest challenges moving forward. Below are some very common use cases for biotechnology most people will have come in contact with already.

It is anything but surprising to learn biotechnology has made a big impact on the medical sector over the past few years. Biotechnology, or more specifically, bio-processing, is used to develop new pharmaceuticals which are often difficult to produce due to purity quality control requirements. Some of the more popular biotech pharmaceuticals include Remicade, Rituxan, Prevarn, and Avastin.

Very few consumers give fabrics a second thought, other than to determine whether the material would rub against the skin. Interestingly enough, most fabrics are dyed through a fermentation vat process. Biochemicals are very common in the production of dyes, polyester, and nylon. It is evident there is some form of biotechnology involved in every piece of synthetic clothing we wear today.

Even though biofuel is not as popular as it could be, the concept holds a lot of merit for the future. Biodiesel helps reduce the carbon impact, which is of great importance to the future of our species. To produce biofuel, one needs specific plant-derived sugars which are then fermented using biotechnology to create ethanol. Further advances in the development of biofuel will see the introducing of alternative compoundsto jet fuel.

It may come as a surprise to find out Goodyear Tire is actively exploring the boundaries of biotechnology. Through a partnership with Genencor, the company is researching synthetic rubber created out of mostly renewable raw materials. In doing so, the company hopes to replace the crude oil requirements necessary to produce a single passenger tie.

As unusual as it may sound, some of the foods we consume on a regular basis are a direct result of biotechnology. Most of the products usedin food and [soft] drinks are processed using biochemicals. Sweeteners, flavors and acidity regulators found in nearly every product are just a few examples of how biotechnology is affecting our daily lives. Even the packaging used by supermarkets is made of biochemicals.

It appears very few people are aware of what can be found in alcoholic beverages these days. The production process of alcohol is a clear example of industrial biotechnology. This process involves converting starch to sugar and fermenting the yeast. Both parts are biotechnology in its simplest form. There is a lot more to the beer in a bottle than meets the eye, that much is certain.

If you liked this article, follow us on Twitter @themerklenews and make sure to subscribe to our newsletter to receive the latest bitcoin, cryptocurrency, and technology news.

Read more:
Top 6 Everyday Products Using Biotechnology - The Merkle

BENGALURU: For all Bioscience graduates pursuing BE, BTech, BSc, MSc, MTech and PhD courses, there is good news for their career. The department of Biotechnology at Sir M Visvesvaraya Institute of Tecnology (MVIT) is organising a three day national seminar on Entrepreneurial Opportunities in Biotechnology from March 23 - 25 at its campus. The seminar that is also open to inquisitive parents, energetic alumni, enthusiastic faculty and industry experts is expected to alleviate the many concerns of graduates and their parents regarding their future prospects and career development. HG Nagendra, professor and head of the Biotechnology department, said: "The focus of education is to not only train the students in curriculum defined skillsets but also to guide them towards realising their higher aspirations." The seminar includes invited plenary talks by subject experts, panel discussions, industry-academia interactive sessions, poster sessions, project idea presentations, several stalls and displays. Cash awards will be awarded to those with best presentations and networking at the seminar.

Read the original post:
MVIT organises three-day national seminar on Biotechnology - Times of India

Dr Kalpana Joshi shares her thoughts with BioSpectrum on current biotech education and the academia-industry gap

Dr Kalpana Joshi is Professor and Head of the Department of Biotechnology at Sinhgad College of Engineering (SCOE). The institute is affiliated to Savitribai Phule Pune University (SPPU) and recognised by All India Council for Technical Education (AICTE), New Delhi. Recently, SCOE has received NAAC "A" Grade. BTech Biotechnology course run by the department is first AICTE approved course in SPPU. Dr Joshi completed her doctorate in molecular biology from National Chemical Laboratory. She headed in-vitro biology group at Pharma R and D, besides giving consultancy to pharma companies like Glenmark, Matrix, Hyderabad and Orchids, Chennai. The SCOE department has a team of faculty with expertise in fermentation engineering, biochemical engineering, pharma biotechnology, biochemistry, analytical chemistry and microbiology. Faculty is active in fetching grants for research, patents and publications. Dr Joshi shares her thoughts with BioSpectrum on current biotech education and the academia-industry gap

Do you think biotech schools are teaching what industry needs?

Field of biotechnology is ever expanding and evolving. Pharma companies have diversified into production and business of biotherapeutics, vaccines and immunologicals, and molecular diagnostics. Industries such as agri-biotech, dairy biotech, food biotech are coming up and have specific requirement of skilled manpower. I feel giving hard core fundamental knowledge of the subjects and skill development are essential to meet industry requirement.

Specific requirements of industry when it comes to biotech education?

Industry requires experienced and trained manpower. There is no time for training in companies. I remember my former boss used to tell me Kalpana this is not university for training. Take someone who would work from the next day.' Biotech schools need to develop necessary laboratory skills and strong basics.

Where is the gap according to you?

As a manager in drug discovery R&D of top pharma company, I used to interview candidates from renowned biotech schools in India. Major observation was students lacked practical skills and basic knowledge of fundamental subjects like microbiology, immunology, molecular biology, biochemistry etc. We at SCOE decided to focus on developing strong knowledge and skills in three pillars of biotechnology namely microbiology, biochemistry, and molecular biology with blend of engineering fundamentals like mass transfer, heat transfer, unit operations, plant design and process development. We have created excellent facilities so that students get to handle top brand equipment like PCR, HPLC, Lyophiliser, fermenters, microfiltrations and develop practical skills in molecular biology, animal tissue culture and data analysis softwares. Gap is at many places. I can give examples. Students use graph papers to plot graphs. We need to train them to use Excel to analyse data and plot graphs using softwares like Prism and SPSS normally used by industries

What do you do to bridge the skill gap if it exists?

At Sinhgad Institutes, we have state-of-the-art laboratories where students are trained for developing practical skills in microbiology, enzymology, molecular biology, fermentations and reaction engineering. We also teach them computation and statistics. Students work on projects and develop skills in at least one technique such as PCR, HPLC or cell culture. They are trained to be analytical, logical and develop problem solving capacity. Students are encouraged to do industry internships and projects in collaboration with companies and national laboratories.

What has been the investment in student training?

We have invested in infrastructure, facilities, equipment and faculty. Faculty members are PhD/ MTechs from renowned institutes like NCL, IITs, ICTs with industry exposure. If faculty does not know what is happening in the industry then it is difficult to percolate it to students. We ensure that faculty gets exposure to industry and maintain interactions with industry experts

Link:
Field of biotechnology is ever expanding and evolving - BSI bureau (press release)